A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Hengrui Medicine

Status and phase

Terminated

Phase 2

Conditions

Sarcoma

Treatments

Drug: SHR-1210 plus Apatinib

Drug: ADM plus IFO or IFO alone

Study type

Interventional

Funder types

Industry

Identifiers

SHR-1210-II-212

Details and patient eligibility

About

The main purpose of this study is to evaluate the efficacy of SHR-1210 plus Apatinib versus AMD plus IFO in participants with soft tissue sarcoma.

Enrollment

99 patients

Sex

All

Ages

16 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female subjects with the age from 16 years to 70 years.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;the ECOG performance status of 2 can be accepted after the amputation.
Life expectancy of at least 3 months.
Histologically confirmed diagnosis of advanced unresectable or metastatic soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy.The histopathologic types as specified in the protocol.
Without prior systemic chemotherapy or relapse more than 6 months after the completion of last systemic chemotherapy.
Presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Acceptable liver function, renal function, hematologic status and coagulation function as specified in the protocol.
Females of child-bearing potential must have a negative serum pregnancy test within 7 days prior to randomization.Females of child-bearing potential and males must agree to use highly effective contraceptive precautions during the trial and up to 3 months following the last dose of study drug.
Willingness to comply with the study protocol for any reason.

Exclusion criteria

Receiving any previous anticancer treatment, other investigational drugs or any attenuated live vaccine with 4 weeks of the first does of study drug.
Prior treatment with PD-1/PD-L1/CTLA-4 targeted drugs or VEGFR targeted drugs.
Plan to receive surgery or radiotherapy to treat the sarcoma during the trail.
Radiological evidence of brain metastases or primary tumors.
Diagnosed other malignancies within the last 3 years from the first dose of drug.
Known allergy to any of the treatment components.
Active infection including human immunodeficiency virus (HIV) ,HBV or HCV.
Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.